Phase i trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer

Cancer Immunology, Immunotherapy

Volumn 61, Issue 7, 2012, Pages 1137-1147

  McNeel, Douglas G ^a,b,d   Smith, Heath A ^a   Eickhoff, Jens C ^a,c   Lang, Joshua M ^a,b   Staab, Mary Jane ^a   Wilding, George ^a,b   Liu, Glenn ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d University of Wisconsin Health   (United States)

Author keywords

Anti CTLA 4 monoclonal antibody; Bicalutamide; Clinical trial; Prostate cancer; Tremelimumab

Indexed keywords

BICALUTAMIDE; CP 275206; PROSTATE SPECIFIC ANTIGEN; TICILIMUMAB; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; AMYLASE DISORDER; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ARTICLE; BLEEDING; BLOATING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPNEA; ENDOCRINE DISEASE; EYE DISEASE; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPOTENSION; IMMUNE RESPONSE; KINETICS; LUNG DISEASE; MALE; MASTALGIA; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RECURRENT CANCER; RIGOR; SHORT COURSE THERAPY; SINGLE BLIND PROCEDURE; SKIN MANIFESTATION; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL DISORDER;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84862754605     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1193-1     Document Type: Article

References (48)

1. R Siegel E Ward O Brawley A Jemal 2011 Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 212 236 21685461 10.3322/caac.20121
2. MG Oefelein ND Smith JT Grayhack AJ Schaeffer KT McVary 1997 Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate J Urol 158 1460 1465 9302143 10.1016/S0022-5347(01)64243-5 1:STN:280:DyaK2svksFymtw%3D%3D
3. CR Pound AW Partin MA Eisenberger DW Chan JD Pearson PC Walsh 1999 Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1591 1597 10235151 10.1001/jama.281.17.1591 1:STN:280:DyaK1M3kvFagsg%3D%3D
4. SJ Freedland EB Humphreys LA Mangold M Eisenberger FJ Dorey PC Walsh AW Partin 2005 Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 433 439 16046649 10.1001/jama.294.4.433 1:CAS:528:DC%2BD2MXms1ygsLk%3D
5. SF Slovin AS Wilton G Heller HI Scher 2005 Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy Clin Cancer Res 11 8669 8673 16361552 10.1158/1078-0432.CCR-05-1668 1:CAS:528:DC%2BD2MXhtlWrsb3M
6. AK Lee LB Levy R Cheung D Kuban 2005 Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy Int J Radiat Oncol Biol Phys 63 456 462 15927415 10.1016/j.ijrobp.2005.03.008
7. SJ Freedland EB Humphreys LA Mangold M Eisenberger FJ Dorey PC Walsh AW Partin 2007 Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality J Clin Oncol 25 1765 1771 17470867 10.1200/JCO.2006.08.0572
8. PW Kantoff CS Higano ND Shore ER Berger EJ Small DF Penson CH Redfern AC Ferrari R Dreicer RB Sims Y Xu MW Frohlich PF Schellhammer 2010 Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411 422 20818862 10.1056/NEJMoa1001294 1:CAS:528:DC%2BC3cXhtVGlurrN
9. FS Hodi SJ O'Day DF McDermott RW Weber JA Sosman JB Haanen R Gonzalez C Robert D Schadendorf JC Hassel W Akerley AJ van den Eertwegh J Lutzky P Lorigan JM Vaubel GP Linette D Hogg CH Ottensmeier C Lebbe C Peschel I Quirt JI Clark JD Wolchok JS Weber J Tian MJ Yellin GM Nichol A Hoos WJ Urba 2010 Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711 723 20525992 10.1056/NEJMoa1003466 1:CAS:528:DC%2BC3cXhtVCrtrbN
10. MF Krummel JP Allison 1995 CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J Exp Med 182 459 465 7543139 10.1084/jem.182.2.459 1:CAS:528:DyaK2MXntFKhsL4%3D
11. DR Leach MF Krummel JP Allison 1996 Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1734 1736 8596936 10.1126/science.271.5256.1734 1:CAS:528:DyaK28XhvVWmsLk%3D
12. ED Kwon AA Hurwitz BA Foster C Madias AL Feldhaus NM Greenberg MB Burg JP Allison 1997 Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer Proc Natl Acad Sci USA 94 8099 8103 9223321 10.1073/pnas.94.15.8099 1:CAS:528:DyaK2sXksl2ltrk%3D
13. AA Hurwitz BA Foster ED Kwon T Truong EM Choi NM Greenberg MB Burg JP Allison 2000 Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Res 60 2444 2448 10811122 1:CAS:528:DC%2BD3cXjtV2qt7s%3D
14. C Robert L Thomas I Bondarenko S O'Day M DJ C Garbe C Lebbe JF Baurain A Testori JJ Grob N Davidson J Richards M Maio A Hauschild WH Miller Jr. P Gascon M Lotem K Harmankaya R Ibrahim S Francis TT Chen R Humphrey A Hoos JD Wolchok 2011 Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2517 2526 21639810 10.1056/NEJMoa1104621 1:CAS:528: DC%2BC3MXosVegtro%3D
15. RH Thompson JP Allison ED Kwon 2006 Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer Urol Oncol 24 442 447 16962497 10.1016/j.urolonc.2005.08.011 1:CAS:528:DC%2BD28Xptlyqtrc%3D
16. EJ Small NS Tchekmedyian BI Rini L Fong I Lowy JP Allison 2007 A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 1810 1815 17363537 10.1158/1078-0432.CCR-06-2318 1:CAS:528:DC%2BD2sXivV2gtLs%3D
17. L Fong SS Kwek S O'Brien B Kavanagh DG McNeel V Weinberg AM Lin J Rosenberg CJ Ryan BI Rini EJ Small 2009 Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF Cancer Res 69 609 615 19147575 10.1158/0008-5472.CAN-08-3529 1:CAS:528:DC%2BD1MXltFShtQ%3D%3D
18. HJ Helminen JL Ericsson 1972 Ultrastructural studies on prostatic involution in the rat. Evidence for focal irreversible damage to epithelium, and heterophagic digestion in macrophages J Ultrastruct Res 39 443 455 4556320 10.1016/S0022-5320(72)90112-8 1:STN:280:DyaE383htFejsQ%3D%3D
19. HJ Helminen JL Ericsson M Niemi 1970 Lysosomal changes during castration-induced prostatic involution in the rat Acta Pathol Microbiol Scand [A] 78 493 494 1:STN:280:DyaE3M%2Fis1Ojsg%3D%3D
20. NL Sandford JW Searle JF Kerr 1984 Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation Pathology 16 406 410 6522105 10.3109/00313028409084731 1:CAS:528:DyaL2MXls1egtQ%3D%3D
21. MJ Naslund JD Strandberg DS Coffey 1988 The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis J Urol 140 1049 1053 3172358 1:STN:280:DyaL1M%2Fht1antw%3D%3D
22. CL Robinette 1988 Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate Prostate 12 271 286 2453862 10.1002/pros.2990120310 1:CAS:528:DyaL1cXks1Oisr4%3D
23. L Seethalakshmi RS Bala RK Malhotra T Austin-Ritchie C Miller-Graziano M Menon J Luber-Narod 1996 17 Beta-estradiol induced prostatitis in the rat is an autoimmune disease J Urol 156 1838 1842 8863627 10.1016/S0022-5347(01)65548-4 1:CAS:528:DyaK28XmsFOlu74%3D
24. A Staack AP Kassis A Olshen Y Wang D Wu PR Carroll GD Grossfeld GR Cunha SW Hayward 2003 Quantitation of apoptotic activity following castration in human prostatic tissue in vivo Prostate 54 212 219 12518326 10.1002/pros.10179
25. F Civantos MS Soloway JE Pinto 1996 Histopathological effects of androgen deprivation in prostatic cancer Semin Urol Oncol 14 22 31 8725888 1:STN:280:DyaK28zjvV2hug%3D%3D
26. M Mercader BK Bodner MT Moser PS Kwon ES Park RG Manecke TM Ellis EM Wojcik D Yang RC Flanigan WB Waters WM Kast ED Kwon 2001 T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci USA 98 14565 14570 11734652 10.1073/pnas.251140998 1:CAS:528:DC%2BD3MXptFCks7g%3D
27. MD Morse DG McNeel 2010 Prostate cancer patients treated with androgen deprivation therapy develop persistent changes in adaptive immune responses Hum Immunol 71 496 504 20153396 10.1016/j.humimm.2010.02.007 1:CAS:528: DC%2BC3cXkvFCmt7o%3D
28. CG Drake AD Doody MA Mihalyo CT Huang E Kelleher S Ravi EL Hipkiss DB Flies EP Kennedy M Long PW McGary L Coryell WG Nelson DM Pardoll AJ Adler 2005 Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen Cancer Cell 7 239 249 15766662 10.1016/j.ccr.2005.01.027 1:CAS:528:DC%2BD2MXivFCqu74%3D
29. PM Arlen JL Gulley N Todd R Lieberman SM Steinberg S Morin A Bastian J Marte KY Tsang P Beetham DW Grosenbach J Schlom W Dahut 2005 Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer J Urol 174 539 546 16006888 10.1097/01.ju.0000165159. 33772.5b 1:CAS:528:DC%2BD2MXmtVWrtL0%3D
30. RA Madan JL Gulley J Schlom SM Steinberg DJ Liewehr WL Dahut PM Arlen 2008 Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy Clin Cancer Res 14 4526 4531 18628467 10.1158/1078-0432.CCR- 07-5048 1:CAS:528:DC%2BD1cXosFGitLg%3D
31. JB Aragon-Ching KM Williams JL Gulley 2007 Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer Front Biosci 12 4957 4971 17569623 10.2741/2441 1:CAS:528: DC%2BD2sXosF2qsrk%3D
32. BB Maricque JC Eickhoff DG McNeel 2011 Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer Prostate 71 134 146 20632317 10.1002/pros.21229
33. HA Smith BB Maricque J Eberhardt B Petersen JL Gulley J Schlom DG McNeel 2011 IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy J Biomed Biotech 2011 454861
34. Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES (2011) Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (in press)
35. EJ Dunphy JC Eickhoff CH Muller RE Berger DG McNeel 2004 Identification of antigen-specific IgG in sera from patients with chronic prostatitis J Clin Immunol 24 492 501 15359108 10.1023/B:JOCI.0000040920.96065.5a 1:CAS:528:DC%2BD2cXnsVWqtrs%3D
36. DG McNeel LD Nguyen BE Storer R Vessella PH Lange ML Disis 2000 Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer J Urol 164 1825 1829 11025777 10.1016/S0022- 5347(05)67114-5 1:CAS:528:DC%2BD3cXnslChsrY%3D
37. KY Chung I Gore L Fong A Venook SB Beck P Dorazio PJ Criscitiello DI Healey B Huang J Gomez-Navarro LB Saltz 2011 Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer J Clin Oncol 28 3485 3490 10.1200/JCO.2010.28.3994
38. LH Camacho S Antonia J Sosman JM Kirkwood TF Gajewski B Redman D Pavlov C Bulanhagui VA Bozon J Gomez-Navarro A Ribas 2009 Phase I/II trial of tremelimumab in patients with metastatic melanoma J Clin Oncol 27 1075 1081 19139427 10.1200/JCO.2008.19.2435 1:CAS:528:DC%2BD1MXktVCju7g%3D
39. FS Hodi MC Mihm RJ Soiffer FG Haluska M Butler MV Seiden T Davis R Henry-Spires S MacRae A Willman R Padera MT Jaklitsch S Shankar TC Chen A Korman JP Allison G Dranoff 2003 Biologic activity of cytotoxic T lymphocyte- associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci USA 100 4712 4717 12682289 10.1073/pnas.0830997100 1:CAS:528:DC%2BD3sXjt12nsL4%3D
40. D Keizman M Zahurak V Sinibaldi M Carducci S Denmeade C Drake R Pili ES Antonarakis S Hudock M Eisenberger 2010 Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study Clin Cancer Res 16 5269 5276 20978144 10.1158/1078-0432.CCR-10- 1928 1:CAS:528:DC%2BC3cXhtl2rsLvM
41. PM Arlen F Bianco WL Dahut A D'Amico WD Figg SJ Freedland JL Gulley PW Kantoff MW Kattan A Lee MM Regan O Sartor 2008 Prostate specific antigen working group guidelines on prostate specific antigen doubling time J Urol 179 2181 2185 18423743 10.1016/j.juro.2008.01.099
42. HI Scher M Eisenberger AV D'Amico S Halabi EJ Small M Morris MW Kattan M Roach P Kantoff KJ Pienta MA Carducci D Agus SF Slovin G Heller WK Kelly PH Lange D Petrylak W Berg C Higano G Wilding JW Moul AN Partin C Logothetis HR Soule 2004 Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group J Clin Oncol 22 537 556 14752077 10.1200/JCO.2004.07.099
43. NJ Nesslinger RA Sahota B Stone K Johnson N Chima C King D Rasmussen D Bishop PS Rennie M Gleave P Blood H Pai C Ludgate BH Nelson 2007 Standard treatments induce antigen-specific immune responses in prostate cancer Clin Cancer Res 13 1493 1502 17332294 10.1158/1078-0432.CCR-06-1772 1:CAS:528:DC%2BD2sXitlSjt7g%3D
44. RB Alexander F Brady MS Leffell V Tsai E Celis 1998 Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer Urology 51 150 157 9457311 10.1016/S0090-4295(97)00480-9 1:STN:280:DyaK1c7hvVKgtQ%3D%3D
45. RB Alexander F Brady S Ponniah 1997 Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins Urology 50 893 899 9426720 10.1016/S0090-4295(97)00456-1 1:STN:280:DyaK1c%2FovVWhtA%3D%3D
46. J Yuan S Gnjatic H Li S Powel HF Gallardo E Ritter GY Ku AA Jungbluth NH Segal TS Rasalan G Manukian Y Xu RA Roman SL Terzulli M Heywood E Pogoriler G Ritter LJ Old JP Allison JD Wolchok 2008 CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit Proc Natl Acad Sci USA 105 20410 20415 19074257 10.1073/pnas.0810114105 1:CAS:528:DC%2BD1MXhsFWktA%3D%3D
47. PW Kantoff TJ Schuetz BA Blumenstein LM Glode DL Bilhartz M Wyand K Manson DL Panicali R Laus J Schlom WL Dahut PM Arlen JL Gulley WR Godfrey 2010 Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 1099 1105 20100959 10.1200/JCO.2009.25.0597 1:CAS:528:DC%2BC3cXktF2ltLw%3D
48. S Gnjatic NK Altorki DN Tang SM Tu V Kundra G Ritter LJ Old CJ Logothetis P Sharma 2009 NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells Clin Cancer Res 15 2130 2139 19276258 10.1158/1078-0432.CCR-08-2632 1:CAS:528:DC%2BD1MXjtF2rur0%3D